Table 3.
Changes in SPARC expression over time
| Histology | Primary site | Primary SPARC score | Treatment prior to primary score | Local (L) or distant (D) recurrence | Secondary SPARC score | Treatment prior to secondary score |
|---|---|---|---|---|---|---|
| MPNST | Extremity | 0 | AI | D | 0 | AD |
| SS | Extremity | 0 | GT, XRT | D | 0 | None |
| MPNST | Extremity | 1 | AI | L | 0 | None |
| UPS | Extremity | 1 | AI | D | 2 | GT |
| LMS | Trunk | 1 | AI, XRT | D | 0 | GT |
| UPS | Trunk | 2 | GT | L | 2 | None |
| UPS | Trunk | 2 | AI | L | 4 | None |
| Fibrosarcoma | Extremity | 4 | AI | L | 6 | None |
| Dediff LPS | Trunk | 6 | GT | D | 4 | None |
| UPS | Extremity | 9 | GT | D | 0 | None |
A- doxorubicin, I- ifosfamide, G-gemcitabine, T- docetaxel, D- dacarbazine